1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Polycystic Ovarian Syndrome Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

Polycystic Ovarian Syndrome Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

  • September 2021
  • 175 pages
  • ID: 6151527
  • Format: PDF
  • The Business Research Company


Table of Contents

Major players in the polycystic ovarian syndrome treatment market are Bristol-Myer Squibb Company, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott and Addex Therapeutics Ltd.

The global polycystic ovarian syndrome treatment market is expected to grow from $3.67 billion in 2020 to $3.96 billion in 2021 at a compound annual growth rate (CAGR) of 7.9%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.76 billion in 2025 at a CAGR of 5%.

The polycystic ovarian syndrome treatment market consists of sale of services and related products that are used in hospital pharmacies, drug stores, and retail pharmacies to treat polycystic ovarian syndrome. The polycystic ovarian syndrome is a disorder in which hormones are out of control for females and have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them.

The polycystic ovarian syndrome treatment market covered in this report is segmented by drug type into oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, aromatase inhibitors. It is also segmented by surgery type into ovarian wedge resection and laparoscopic ovarian drilling and by end user into hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, feminist health centers.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market.FDA has not approved pharmacological treatment for use in adolescents with PCOS.

However, some pharmacological interventions are used to treat PCOS symptoms.For instance, rimonabant, a key appetite suppressant cannabinoid CB1 receptor antagonist was not approved by the United States Food and Drug Administration (FDA) in the USA due to concerns about suicidal ideation and drug overdoses.

Moreover, Minoxidil is the only drug approved by FDA, used for the treatment of female pattern baldness. Therefore, the lack of regulatory body approved drugs in many countries is a key factor restraining the growth of the polycystic ovarian syndrome treatment market.

In July 2019, Eurolife Healthcare Pvt. Ltd, a Mumbai based company, manufactures and distributes an exclusive portfolio of healthcare formulations, Intravenous Infusions, Ophthalmic, Sterilized water for Injections, Nebules, Tablets, Capsules, Ointment & Creams, acquired Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition helped the company to tap and service its European and the US markets for intravenous infusions in a better way. Teva Pharmaceutical Industries Ltd., a multinational pharmaceutical company, develops, manufactures, and markets generic and branded human pharmaceuticals, as well as active pharmaceutical ingredients.

The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market.PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities.

The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5% and 6.3% in Sri Lanka, 9.13% in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market.

Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market.Laparoscopic ovarian drilling is a surgical treatment performed by the doctors in critical conditions that can cause ovulation in women with polycystic ovary syndrome (PCOS).

Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and use of fertility drugs. According to the study published in 2019 by the Department of Gynecology and Obstetrics in major hospitals in France, after laparoscopic drilling, 47.4% (137 patients) had pregnancy and 51.8% (71 patients) of these were spontaneous. 16.6% (48 patients) women had at least two pregnancies after drilling and 56.3% (27 patients) of these were spontaneous. 33 women received second drillings. Of these, 57.6% (19 patients) achieved at least one pregnancy, within this 52.6% (10 patients) were spontaneous.

The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on